Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers

NCT03017833 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03017833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03017833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
March 12, 2018
Completion date
December 21, 2022
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, metastatic malignant solid neoplasm, recurrent malignant solid neoplasm, refractory neoplasm